@article{3220417,
    title = "Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study",
    author = "Sanchorawala, V. and Palladini, G. and Minnema, M.C. and Jaccard, A. and Lee, H.C. and Gibbs, S. and Mollee, P. and Venner, C. and Lu, J. and Schönland, S. and Gatt, M. and Suzuki, K. and Kim, K. and Cibeira, M.T. and Beksac, M. and Libby, E. and Valent, J. and Hungria, V. and Wong, S.W. and Rosenzweig, M. and Bumma, N. and Chauveau, D. and Gries, K.S. and Fastenau, J. and Tran, N.P. and Qin, X. and Vasey, S.Y. and Weiss, B.M. and Vermeulen, J. and Ho, K.F. and Merlini, G. and Comenzo, R.L. and Kastritis, E. and Wechalekar, A.D.",
    journal = "American Journal of Hematology",
    year = "2022",
    volume = "97",
    number = "6",
    pages = "719-730",
    publisher = "John Wiley and Sons Inc",
    issn = "0361-8609, 1096-8652",
    doi = "10.1002/ajh.26536",
    abstract = "In the phase 3 ANDROMEDA trial, patients treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone (D-VCd) had significantly higher rates of organ and hematologic response compared with patients who received VCd alone. Here, we present patient-reported outcomes (PROs) from the ANDROMEDA trial. PROs were assessed through cycle 6 using three standardized questionnaires. Treatment effect through cycle 6 was measured by a repeated-measures, mixed-effects model. The magnitude of changes in PROs versus baseline was generally low, but between-group differences favored the D-VCd group. Results were generally consistent irrespective of hematologic, cardiac, or renal responses. More patients in the D-VCd group experienced meaningful improvements in PROs; median time to improvement was more rapid in the D-VCd group versus the VCd group. After cycle 6, patients in the D-VCd group received daratumumab monotherapy and their PRO assessments continued, with improvements in health-related quality of life (HRQoL) reported through cycle 19. PROs of subgroups with renal and cardiac involvement were consistent with those of the intent-to-treat population. These results demonstrate that the previously reported clinical benefits of D-VCd were achieved without decrement to patients' HRQoL and provide support of D-VCd in patients with AL amyloidosis. © 2022 Wiley Periodicals LLC."
}